Hi Thymus, long time no speak. I can’t remember the exact price but there were a few things not lining up that got me out and partnering was one of them, also other questions around effectiveness but mainly why can’t it be partnered. ACL was the other one that stands out to me, I rode the Fondaparinux approval and went through the ups and downs but HA-Irrinotecan ph 3 trial was suspect to me. In both occasions I had spoken to Mercer (TIS) about trial
Partners and Peter Smith (ACL) also about the same. I had seen both companies were active on potential partnering websites and certain biotech summits they attended were designed for partnering opportunities so why be there if that’s not what you’re chasing. Both had the same sort of line of “we just haven’t found the right partner” and things like “We want the best deal for shareholders so we are going it alone” etc etc.
I almost made the mistake of riding the ACL results and bought back in but luckily sold out not a week later remembering my plans and investing strategies. These strategies obviously had come from painful and hard learnt lessons, so sticking with them was an easy choice in the end.
GL all, maybe we can grab a drink at an AGM some day Thymus, I’d prefer it to be a celebratory one after a great AGM!
Add to My Watchlist
What is My Watchlist?
